ORIC Pharmaceuticals, Inc. (ORIC) Stock Forecast
ORIC analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 16 analysts
- Price target
- $21.64 average of analyst targets
- Upside to target
- +75.2% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.40
- 52-week range
- $7.47 – $14.65
ORIC analyst ratings
16 analystsNumber of analysts at each rating.
ORIC price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ORIC earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.38 | −$0.45 | −$0.32 | −$0.33 | −14.8% | 13 |
| Current fiscal year (2026) | −$1.49 | −$1.64 | −$1.25 | −$1.47 | −1.3% | 13 |
| Next fiscal year (2027) | −$1.67 | −$1.91 | −$1.37 | −$1.49 | −12.4% | 13 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ORIC revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 14 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 14 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 13 |
ORIC EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ORIC EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.37 | −$0.38 | −$0.37 | −$0.38 | −$0.38 | +1.7% | 0 up · 1 down |
| Current fiscal year (2026) | −$1.47 | −$1.48 | −$1.48 | −$1.49 | −$1.49 | +1.4% | 0 up · 1 down |
| Next fiscal year (2027) | −$1.60 | −$1.61 | −$1.61 | −$1.67 | −$1.67 | +4.3% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ORIC earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ORIC beat in 6 of 12.
What analysts expect from ORIC
16 analysts cover ORIC Pharmaceuticals; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $21.64, 75.2% above the latest close of $12.35. Analysts expect earnings of −$1.49 per share for 2026, −1.3% from a year earlier. For 2027 the average estimate is −$1.67 per share. ORIC Pharmaceuticals beat the EPS estimate in 6 of the last 12 quarters.
Related: ORIC income statement, ORIC key metrics, ORIC chart. See the ORIC stock overview for the latest quote and news.
ORIC forecast FAQ
What is ORIC Pharmaceuticals's price target?
The average analyst price target for ORIC Pharmaceuticals is $21.64, 75.2% above the latest close of $12.35.
Is ORIC Pharmaceuticals a buy, hold or sell?
Of 16 analysts covering ORIC Pharmaceuticals, 13 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is ORIC Pharmaceuticals's EPS forecast?
Analysts forecast −$1.49 per share for 2026 (range −$1.64 to −$1.25); for 2027 the estimate is −$1.67.
When does ORIC Pharmaceuticals report earnings?
ORIC Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.40.
Does ORIC Pharmaceuticals usually beat earnings estimates?
ORIC Pharmaceuticals reported EPS at or above the analyst estimate in 6 of the last 12 quarters.